In the last years, RNA interference (RNAi) has begun to emerge as a promising technology to be applied to therapeutics. We have focused our interests in complementing the existing pharmacological approaches to glaucoma with the application of siRNA for some targets such as alpha and beta adrenergic receptors and carbonic anhydrases. We have designed siRNA for the following adrenergic receptor genes: beta1, beta2 , alpha1A and alpha1B. Concerning the carbonic anhydrases (CA) CAII, CAIV and CAXII were silenced. siRNAs were administered in saline solution (0.9% w/v) to a final volume of 40ml in one eye during four consecutive days and the opposite eye was taken as a control applying 40ml of sterile saline (0.9% w/v). Alpha adrenergic silencing produced a reduction of intraocular pressure (IOP) between 17 and 20 %, these effects lasting for 80 hours. Beta adrenergic silencing was more effective since siRNA against these targets reduced IOP between 20 and 30 %, their effects lasting at least 100 hours. Carbonic anhydrase II silencing reduce IOP 30% (mean time effect 110 hours), CAIV reduced IOP 18 % with a mean time effect of 78 hours and CAXII reduced intraocular pressure 21 % its mean time effect being 60 hours. The reduction of IOP with siRNA against alpha and beta adrenoceptors as well carbonic anhydrases CAII, CAIV and CAXII, were comparable with those produced by commercial products. Moreover, siRNA have the advantage of presenting a long lasting effect compared to commercial pharmaceutical products.